Additional file 3: Figure S2. TransCon TLR7/8 Agonist inhibited CT26 tumor growth in a dose-dependent manner. Female BALB/c mice were SC implanted with 3 x 105 CT26 tumor cells in their flank. When tumors were grown to a mean tumor volume of ~115 mm3, mice were randomized into treatment cohorts (Day 0; n = 17/group). The day following randomization, animals received either empty hydrogel (TransCon Vehicle) or 5, 20, 80, or 200 μg (eq. of resiquimod) of TransCon TLR7/8 Agonist as a single intratumoral dose (arrow). Values are represented as mean tumor volume ± SEM. On Day 10, * = p